Md Ibrahim, PhD., M.Pharm

Assistant Professor

Phone: (916) 686-7396
md.ibrahim@cnsu.edu

About

Dr. Md Ibrahim is a pharmaceutical and biomedical scientist with extensive academic and research experience. His expertise spans DNA damage repair, resistance to PARP and PARG inhibitors, replication-associated base excision repair (R-BER), the impact of cancer on pulmonary vasculature, drug-induced pulmonary arterial hypertension (PAH), and early cancer detection through circulating cancer cells.
Dr. Ibrahim trained as a pharmacist in Bangladesh and earned his Ph.D. in Biomedical Sciences, with a specialization in Cancer Biology, from Mitchell Cancer Institute (MCI), USA under the mentorship of Dr. Robert W. Sobol. His doctoral research focused on elucidating mechanisms of DNA damage repair, specifically targeting replication stress-induced PARP1/PARP2 activation and strategies to overcome resistance to cancer therapies.
Before joining our faculty, Dr. Ibrahim held several academic and research positions, including Senior Scientist at Vascular Biosciences (California) and Principal Scientist at Medluidics (California).

Research Interest

1. Understanding replication stress associated PARP activation.
2. Understanding replication-associated base excision repair (R-BER)
3. Exploring the interplay between different DNA damage repair pathways during replication and their implications for cancer therapy, using advanced technologies such as CRISPR, Split TurboID, and proteomics.
4. Applying artificial intelligence (AI) to cancer therapy resistance and early cancer detection.
5. Leveraging advanced microfluidic "organ-on-a-chip" technologies for drug screening, biomarker discovery, and therapeutic innovations.
6. Developing novel therapeutic strategies aimed at targeting previously non-targetable DNA damage repair pathways, with the potential to treat a wide range of cancers including ovarian, breast, lung cancer, and glioblastoma.

Dr. Ibrahim is actively involved in NIH-funded projects aimed at understanding and treating drug-induced pulmonary arterial hypertension (D-PAH). He is a member of prestigious scientific societies, including the American Association for Cancer Research (AACR), the American Association of Pharmaceutical Scientists (AAPS), and the Biomedical Engineering Society (BMES).